Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larrán A, Gómez M, Barba P, Mata MI, González-Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Hernández-Boluda JC, et al. Ann Hematol. 2015 Jun;94(6):911-8. doi: 10.1007/s00277-015-2330-2. Epub 2015 Feb 14. Ann Hematol. 2015. PMID: 25680896
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.
Barbui T, Ghirardi A, Carobbio A, Masciulli A, Carioli G, Rambaldi A, Finazzi MC, Bellini M, Rumi E, Vanni D, Borsani O, Passamonti F, Mora B, Brociner M, Guglielmelli P, Paoli C, Alvarez-Larran A, Triguero A, Garrote M, Pettersson H, Andréasson B, Barosi G, Vannucchi AM. Barbui T, et al. Blood Cancer J. 2022 Nov 16;12(11):156. doi: 10.1038/s41408-022-00743-0. Blood Cancer J. 2022. PMID: 36385103 Free PMC article. No abstract available.
A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3 inhibition.
Jiménez-Vicente C, Garrote M, López-Guerra M, Villamón E, Guijarro F, Perez-Valencia AI, Martinez-Roca A, Balaguer O, Álvarez-Larrán A, Hernández-Boluda JC, Rovira M, Colomer D, Diaz-Beyá M, Rozman M, Esteve J. Jiménez-Vicente C, et al. Leuk Lymphoma. 2024 Mar;65(3):394-398. doi: 10.1080/10428194.2023.2295788. Epub 2023 Dec 20. Leuk Lymphoma. 2024. PMID: 38117930 No abstract available.
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F, Hernández-Boluda JC, Steegmann JL, Conde E, Alvarez-Larrán A, López-Jiménez J, Osorio S, Villalón L, Camós M, García-Conde J, Odriozola J. Cervantes F, et al. Haematologica. 2003 Oct;88(10):1117-22. Haematologica. 2003. PMID: 14555307 Clinical Trial.
163 results